| Imatinib-Mesylate Induced Interstitial Pneumonitis in Two CML Patients. |
|
Tae Hoon Kim, Byung Gyu Kim, Sung Woo Cho, Sung Kyun Cho, Hyun Jung Kim, Young Jin Yuh, Sung Rok Kim |
1Department of Internal Medicine, Sanggye-Paik Hospital, Inje University College of Medicine, Seoul, Korea. yjyuh@paik.ac.kr
2Department of Pathology, Sanggye-Paik Hospital, Inje University College of Medicine, Seoul, Korea. |
|
|
| Abstract |
|
Imatinib mesylate, a selective inhibitor of BCR-ABL kinase activity, has demonstrated significant clinical efficacy in the treatment of chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs). It has become the standard of treatment for these diseases. Although the toxicity profile of imatinib is superior to that of interferon or other cytotoxic agents, some adverse events including edema, gastrointestinal toxicities and hematologic toxicities are commonly observed in the patients treated by imatinib. We present two cases of imatinib induced interstitial pneumonitis during the treatment of a chronic phase of CML. |
| Key Words:
imatinib mesylate, Lung Diseases, Interstitial, Chronic Myeloid Leukemia |
|
PDF Links
Full text via DOI
Download Citation
